LAST CLOSE: €63.1. (GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis and other indications. No pricing data is available for this time frame, Galapagos, Gilead Halt Trials of Lung-Disease Treatment, Cathie Wood Cites Younger Analysts as Ark's 'Secret Weapon', Generaal De Wittelaan L11 A3 Revenues and other income from continuing operationsOur revenues and other income from continuing operations for the first three months of 2021 increased to €124.2 million compared to €103.6 million in the first three months of 2020. About Galapagos Galapagos NV (Euronext & NASDAQ: GLPG) discovers, develops and commercializes small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. More information at www.glpg.com. At that level they are trading at 9.7% discount to the analyst consensus target price of 0.00. Study uses mobile device technology to support capture of patient-reported outcomes during early and ongoing use of study treatment amongst patients with rheumatoid arthritis Mechelen, Belgium; 18 May 2021; 22.01 CET; – Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the first patient has been enrolled in the FILOSOPHY Phase 4 European real-world outcomes study. Each subscription right gives the right to subscribe to one new Galapagos share. The subscription rights have an exercise term of eight years as of the date of the offer and have an exercise price of €64.76 (the closing price of the share on Euronext Amsterdam and Brussels on the day preceding the date of the offer). Industriepark Mechelen Noord GLPG:EN Brussels Stock Quote - Galapagos NV - Bloomberg Markets. Results from continuing operationsWe realized a net loss from continuing operations of €12.8 million for the first three months of 2021, compared to a net loss of €52.3 million for the first three months of 2020. These risks, uncertainties and other factors include, without limitation, the inherent risks associated with clinical trial and product development activities, including the FILOSOPHY study, competitive developments, and regulatory approval requirements, the risk that the results of the FILOSOPHY study will not support continued approval of Jyseleca for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs) due to safety, efficacy or other reasons, Galapagos’ reliance on collaborations with third parties, including the collaboration with Gilead for filgotinib, risks related to the implementation of the transition of European commercialization responsibility to us, as well as those risks and uncertainties identified in our Annual Report on Form 20-F for the year ended 31 December 2020 and our subsequent filings with the SEC. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations. Get the latest Galapagos NV (GLPG) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Galapagos’ total share capital currently amounts to €354,359,437.71; the total number of securities conferring voting rights is 65,511,581, which is also the total number of voting rights (the “denominator”), and all securities conferring voting rights and all voting rights are of the same category. Attachment PDF version. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. 13,358.60. Find the latest Galapagos NV (GLPG) stock quote, history, news and other vital information to help you with your stock trading and investing. About GLPG. Belgium. Galapagos NV - ADR Stock Forecast, GLPG stock price prediction. The company issued 3,800,000 shares at a price of $42.43 per share. Introduction. Go to www.glpg.com to access the live audio webcast. Stock analysis for Galapagos NV (GLPG:EN Brussels) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Analysts covering Galapagos NV currently have a consensus Earnings Per Share (EPS) forecast of -4.469 for the next financial year. With the enormous amount of cash infused into GLPG by Gilead, the company already has a market cap nearing $12bn against our base case of $9bn, with share price being $185 today. That said, GLPG could be viewed as a takeover target. Find real-time GLPG - Galapagos NV stock quotes, company profile, news and forecasts from CNN Business. FILOSOPHY will enable the gathering of comprehensive real-world data in a population that may not be fully represented in clinical trials, as randomized, placebo-controlled trials require strict patient inclusion criteria. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. The subscription rights as such will not be listed on any stock market. Free forex prices, toplists, indices and lots more. More information at www.glpg.com. GLPG Stock Price | Galapagos N.V. Stock Quote (Netherlands: Euronext Amsterdam) | MarketWatch. Share your opinion and gain insight from other stock traders and investors. Total net decrease in cash and cash equivalents and current financial investments amounted to €54.6 million during the first three months of 2021, compared to a net decrease of €58.4 million during the first three months of 2020. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis and other indications. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. This excludes the 2,736,250 subscription rights of Subscription Right Plan 2021 BE, Subscription Right Plan 2021 RMV and Subscription Right Plan 2021 ROW, which were created subject to acceptance. Secondary and exploratory objectives include effectiveness, evaluation of the effect of filgotinib on patient reported outcomes (PROs) including on pain, fatigue and work productivity, rate of adverse events (AEs) and serious adverse events (SAEs) as well as adverse events of interest, including serious and opportunistic infections (including herpes zoster), major adverse cardiovascular events (MACE), venous thromboembolism (VTE), hyperlipidemia, malignancies, non-melanoma skin cancer (NMSC), and gastrointestinal (GI) perforation. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, … The company issued 3,800,000 shares at a price of $42.43 per share. The archived webcast will also be available for replay shortly after the close of the call. We reported an operating loss amounting to €50.8 million for the first three months of 2021, compared to an operating loss of €46.2 million for the same period last year. Finally, our balance sheet on 31 March 2021 held a receivable from the French government (Crédit d’Impôt Rechercheiv) and a receivable from the Belgian Government for R&D incentives, for a total of both receivables of €142.3 million. Gilead submitted the new drug application in Japan for the treatment of ulcerative colitis (UC). Analysts covering Galapagos NV currently have a consensus Earnings Per Share (EPS) forecast of -4.439 for the next financial year. I am/we are long GLPG. We are encouraged by the primary endpoint outcome with the MANTA/RAy semen parameter studies as we await the Committee for Medicinal Products for Human Use (CHMP) opinion in UC. 34,327.79. Galapagos (GLPG) stock price, charts, trades & the US's most popular discussion forums. The operational cash burn for the three months ended 31 March 2021 amounted to €127.7 million and can be reconciled to our cash flow statement by considering the increase in cash and cash equivalents of €379.1 million, adjusted by (i) the cash proceeds from capital and share premium increase from the exercise of subscription rights by employees for €2.3 million, (ii) the net sale of current financial investments amounting to €475.8 million, and (iii) the cash in from sale of subsidiaries, net of cash disposed of, of €28.7 million. All agenda items were approved, including the re-appointments of Ms. Katrine Bosley and Dr. Raj Parekh as members of the supervisory board, and approval of the remuneration report.
Edge Hockey Sticks, Rocketman Song In Movie, Acer Predator Logo Vector, Ethan Mbappé Transfermarkt, Defunct Speedway Tracks, Owen Hargreaves Alex Ferguson Book, National Museum Of The Philippines Open 2021, Mackie Y Lennox,
